Abstract:Background: Albuvirtide is a once-weekly injectable HIV-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs. Methods: We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on WHO-recommended first-line treatment for > 6 months with a plasma viral load > 1000 copies per mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies per mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%. Findings: At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies per mL (difference: 14.4%, 95% CI: -3.0 to 31.9), meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated (94.9% vs. 74.4%, difference: 20.5%, 95% CI: 5.7 to 35.2, p=0.01). The frequency of grade 3-4 adverse events was similar in the two groups (14.0% vs. 11.1%); the most common adverse events were diarrhea (8.6% vs. 14.1% for the ABT and NRTI groups, respectively), upper respiratory tract infections (4.3% vs. 6.1%), and grade 3-4 increases in triglyceride concentration (6.5% vs. 4.0%). Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received TDF than in those of the ABT group (mean change in eGFR: -11.47 vs. -1.22 mL/min/1.73m2, p=0.02). Interpretation: The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis suggests that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Clinical Trial Number: This study is registered with ClinicalTrials.gov, number NCT02369965 and with the Chinese Clinical Trial Registry, number ChiCTR-TRC-14004276. Funding Statement: This work was supported by the Frontier Biotechnologies Inc., Ministry of Science and Technology of China (Grant No. 2013ZX09101001, 2017ZX09201007), the Beijing Municipal of Science and Technology Major Project (D141100000314005, D141100000314002, D161100000416003), the National Natural Science Foundation of China (81772165, 81571973), and Beijing Key Laboratory for HIV/AIDS Research (BZ0089). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Declaration of Interests: The authors of this manuscript have read the journal's policy and have the following competing interests: CY, RL, JH, and DX have received salary support from Frontier Biotechnologies Inc. All authors had full access to all study data and analyses, and approved the final report. All other authors have declared that no competing interests exist.Ethics Approval Statement: The institutional ethics committee at each site reviewed and approved the protocol and the written informed consent form which was provided according to the declaration of Helsinki. Each patient gave written informed consent before undergoing study procedures. The methods were carried out in accordance with approved guidelines and regulations.

562. Management and Outcomes of Patients With Acute HIV Infection in an Expanded Testing and Linkage to Care Program

Efficacy and Safety of Long Acting HIV Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with HIV-1: Interim 48 Week Results from the Randomized, Controlled, Phase 3 Trial, Non-Inferiority TALENT Study

Long-acting HIV Fusion Inhibitor Albuvirtide Combined with Ritonavir-Boosted Lopinavir for HIV-1-infected Patients after Failing the First-Line Antiretroviral Therapy: 48-Week Randomized, Controlled, Phase 3 Non-Inferiority TALENT Study

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial

Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection

Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries

Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up

Blood Center Testing Allows the Detection and Rapid Treatment of Acute and Recent HIV Infection

917. Accessible HCV Care for People Who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program Versus Facilitated Referral

How important is the acute phase in HIV epidemiology?

Trends in continuity of treatment among children and adolescents living with HIV in 14 districts in South Africa from 2018-2023: A retrospective program analysis

Veteran's Health Administration HIV Care Continuum: 2019 vs 2022

Viral load criteria and threshold optimization to improve HIV incidence assay characteristics

Impact of Expanded HIV Testing and Rapid Antiretroviral Therapy Initiation in Southwest China: an Interrupted Time-Series Analysis.

Understanding the effects of universal test and treat on longitudinal HIV care outcomes among South African youth: a retrospective cohort study

Identification of antibody targets associated with lower HIV viral load and viremic control

Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South

Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection

2496. Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden

Effective Treatment of Patients Experiencing Primary, Acute HIV Infection Decreases Exhausted/Activated CD4+ T Cells and CD8+ T Memory Stem Cells

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018